Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03250507 · ClinicalTrials.gov registry record · Phase 4

Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy

A Phase 4 study of Hysterectomy, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
90
Enrollment target
1
Study location

NCT03250507: Completed Phase 4 study of Hysterectomy, sponsored by Henry Ford Health System.

NCT03250507 is a Phase 4 study of Hysterectomy that has completed, run by Henry Ford Health System. The registered enrollment target is 90 participants, below the 128-participant average among 8 other Hysterectomy trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03250507, a Phase 4 study of Hysterectomy, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the effectiveness of different formulations of bupivacaine infiltrated into the transversus abdominis plane (TAP) on post-operative pain management after open abdominal hysterectomy.

Primary Outcome

Total opioid consumption

Conditions Studied

Interventions

  • DRUG Bupivacaine
  • DRUG Saline
  • DRUG Liposomal bupivacaine

Study Locations (1)

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-03-13
Est. Completion 2019-01-30
Phase Phase 4
Henry Ford Health System

234 total trials

What the finished NCT03250507 record still lists

NCT03250507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 128-participant average among 8 other Hysterectomy trials with a reported enrollment target (30% lower).

The record links to 1 condition, with Hysterectomy appearing as the primary indexed condition, and to 3 interventions - of which Bupivacaine is the first listed.

NCT03250507 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT03250507 about?

NCT03250507 is a clinical study titled "Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy". The goal of this study is to evaluate the effectiveness of different formulations of bupivacaine infiltrated into the transversus abdominis plane (TAP) on post-operative pain management after open abdominal hysterectomy.

What is the current status of trial NCT03250507?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2017-03-13. Estimated completion is 2019-01-30.

What conditions does trial NCT03250507 study?

This clinical trial studies the following conditions: Hysterectomy.

What interventions are being tested in trial NCT03250507?

The interventions under investigation include: Bupivacaine (DRUG), Saline (DRUG), Liposomal bupivacaine (DRUG).

Who is sponsoring clinical trial NCT03250507?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03250507 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hysterectomy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03250507's enrollment target sits among peer trials

90 6th of 8 higher than 3 of 8 other Hysterectomy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hysterectomy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03250507, the US trial registry maintained by the National Library of Medicine. NCT03250507 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.